Spasmalgon, 2 ml 10 pcs

Spasmalgon cjlth;bn non-narcotic analgesic sodium metamizole, myotropic antispasmodic agent pitophenone and m-cholinoblocking agent phenpiveryinia bromide.

Pitophenone, like papaverine, has a direct myotropic effect on the smooth muscles of internal organs and causes them to relax.

Sodium metamizole is a derivative of pyrazolone. It has analgesic, antipyretic and anti-inflammatory action.

Phenpiperinia bromide has an additional relaxing effect on the smooth muscles due to its m-cholin-blocking action.

The combination of the three components of the drug leads to pain relief, relaxation of smooth muscles, and reduction of elevated body temperature.

Indications

Migraine, Biliary dyskinesia, Pain after injuries and operations, Radiculitis, Lumbago, Arthrosis and arthritis, Urinary colic, Gallic colic, GI spasms, Colic, Colitis, Back pain, Headache, Pain in the muscles (myalgia), Neuralgia (pain along the nerves), Colds, Acne (vulgar), Toothache, Pain in the neck, Menstrual pain (algodysmenorrhea), Fever, Sciatica, Rheumatoid arthritis.ul>

.

Active ingredient

Sodium metamizole, Pitofenone, Phenpiperinia bromide

Composition

1 ml contains sodium metamizole 500 mg,

pitophenone hydrochloride 2 mg and phenpiperinia bromide 20 µg.

.

How to take, the dosage

In adults, Spasmalgon is administered 2-5 ml of the solution in m/m or v/v 2 ml 2-3 times per day. Maximum daily dose should not exceed 10 ml. The duration of treatment is not more than 5 days.

In children intravenously and intravenously administered depending on age in the following single doses:
3-11 months. 0.1 ml, 1-4 years 0.2 ml, 5-7 years 0.4 ml, 8-11 years 0.5 ml, 12-14 years 0.8 ml.

If necessary, the drug can be repeated in the same doses.

Interaction

The concomitant use of the drug with X-ray contrast agents, colloidal blood substitutes and penicillin is contraindicated.

Concomitant use of the drug with cyclosporine decreases the concentration of the latter in the blood.

When used concomitantly, methamisole sodium displaces oral hypoglycemic agents, indirect anticoagulants, GCS and indomethacin from binding to protein and increases their activity.

When used concomitantly, phenylbutazone, barbiturates and other inducers of microsomal liver enzymes reduce the effectiveness of metamizole sodium.

Concomitant use with other non-narcotic analgesics, tricyclic antidepressants, oral hormonal contraceptives and allopurinol may increase toxicity.

When used concomitantly, sedatives and anxiolytics (tranquilizers) increase the analgesic effect of Spasmalgon.

Concomitant use of thiamazole and cytostatics increases the risk of leukopenia.

Concomitant use of the drug increases the effect of codeine, histamine H2-receptor blockers and propranololol (slows down inactivation).

Drugs with myelotoxic effect increase the hematotoxic effect of Spasmalgon when used concomitantly.

The co-administration with histamine H1-receptor blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine may increase the m-cholinoblocking effect.

The use together with chlorpromazine or other phenothiazine derivatives may lead to significant hyperthermia.

In concomitant use Spasmalgon increases the effects of ethanol.

Pharmaceutical interactions

Because of the high likelihood of developing pharmaceutical incompatibility, it should not be mixed with other medicinal products in the same syringe.

Special Instructions

Alcohol should not be taken during treatment with the drug.

The use of the drug in breastfeeding mothers requires discontinuation of breastfeeding.

The effect of the drug on the ability to drive vehicles and other mechanisms requiring high concentration

When using the drug it is necessary to monitor peripheral blood count (leukocyte count) and liver function.

In case of suspected agranulocytosis or thrombocytopenia the drug should be discontinued.

During treatment, it is not recommended to drive vehicles and to engage in potentially dangerous activities requiring rapid physical and mental reactions.

.

Contraindications

• inhibition of medullary hematopoiesis;
• stable and unstable angina pectoris;
• high sensitivity to pyrazolone derivatives (butadion, tribuzone), other components of the drug;
• Chronic heart failure in decompensation;
• tachyarrhythmia;
• closed-angle glaucoma;
• prostate hyperplasia;
• intestinal obstruction and megacolon;
• granulocytopenia;
• deficiency of glucose-6-phosphate dehydrogenase;
• pregnancy and lactation;
• children under 6 years.

With caution: mild to moderate degree of hepatic or renal dysfunction; predisposition to arterial hypotension (systolic blood pressure <100 mm Hg); proneness to bronchospasm; hypersensitivity to non-steroidal anti-inflammatory drugs or non-narcotic analgesics.

.

Side effects

Digestive system disorders: burning sensation in the epigastric region, dry mouth.

Nervous system disorders: headache, dizziness, anticholinergic effects (decreased sweating, paresis of accommodation, difficulty in urination).

Cardiovascular system: decreased blood pressure, tachycardia, cyanosis.

Urinary system disorders: impaired renal function, oliguria, anuria, proteinuria, interstitial nephritis, staining of urine red.

Hematopoietic organs: with prolonged use – thrombocytopenia, leukopenia, agranulocytosis.

Allergic reactions: urticaria, bronchospastic syndrome, anaphylactic shock, Quincke’s edema, erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).

.

Overdose

Symptoms: vomiting, dry mouth, decreased perspiration, impaired accommodation, decreased blood pressure, drowsiness, confusion, liver and kidney dysfunction, seizures.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

.

Pregnancy use

It is contraindicated in pregnancy.

Breastfeeding should be stopped during treatment.

.

Similarities

Spasmalin, Maxigan, Bral, Spazgan, Revalgin